Article Text

Download PDFPDF

2022-RA-1388-ESGO Comparison of disease free interval among cervical cancer patients who underwent concurrent chemoradiation for 10 years at a single institution in Korea; What about cervical adenocarcinoma?
  1. ChanJoo Kim1,
  2. Su Jeong Lee2,
  3. Jin Hwi Kim2 and
  4. Tae Chul Park2
  1. 1Department of Obstetrics and Gynecology, The Catholic University of Korea, Uijeongbu, Korea, Republic of
  2. 2Department of Obstetrics and Gynecology, The Catholic University of Korea, Uijenongbu, Korea, Republic of


Introduction/Background The incidence of cervical cancer has been steadily decreasing in Korea since 1999. In addition, the survival propensity for patients with localized cervical squamous cell carcinoma and adenocarcinoma has gradually increased since the introduction of clinical recommendations for platininum-based chemoradiation therapy (CCRT).

Methodology We searched the case records of cervical cancer patients who received CCRT treatment at the Catholic University of Korea Uijeongbu St. Mary’s Hospital from January 1, 2010 to June 30, 2021. A total of 134 patients were enrolled, of which 63 received CCRT as primary treatment and 70 received postoperative adjuvant radiotherapy (RT). Descriptive statistics were used to summarize patient. For the estimation of disease free interval, Kaplan-Meier analysis was performed.

Results The mean age was 57.4 years (range: 32–88 years). Squamous cell carcinoma was the most common type in 107 patients (79.9%), adenocarcinoma in 25 patients (18.7%), and adenosquamous cell type in 2 patients (1.5%). FIGO IIb was the most common with 65 (48.5%), and those with IIa or lower were 42 (31.3%). The mean follow-up period was 39.4 months (2–123 months). The 5-year disease-free survival (DFS) across arms was 56%. In the case of adenocarcinoma patients, although the number of subjects was relatively small, the 5-year DFS was 79% for those who received adjuvant CCRT after surgery (compared with 55% inr SCCA, no statistical significance)

Conclusion With the introduction of CCRT, the therapeutic effect is gradually increasing in patients with 2 types of cervical cancer. For cervical adenocarcinoma, which has been increasing relatively since the introduction of the HPV vaccine, surgical treatment needs to be considered and future studies are also needed in the future.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.